L-Asparaginase, vincristine, and prednisone for induction of first remission in acute lymphocytic leukemia.
L-Asparaginase, vincristine, and prednisone for induction of first remission in acute lymphocytic leukemia.
复制标题
L-天冬酰胺酶、长春新碱和泼尼松用于诱导急性淋巴细胞白血病的首次缓解。
作者：
J. Ortega;M. Nesbit;M. Donaldson;R. Hittle;J. Weiner;M. Karon;D. Hammond
本文报告了在长春新碱和强的松基础上加用门冬酰胺酶诱导急性淋巴细胞白血病和急性未分化白血病首次缓解815例。这种组合导致93%的总体缓解率。在使用泼尼松和长春新碱的标准诱导方案中添加L-天冬酰胺酶并没有显著增加诱导期间的发病率或死亡率。最常见的副作用是短暂的L-门冬酰胺酶诱导的高血糖。L-门冬酰胺酶肌肉注射的安全性和6000 I.U./ m已确认。因此，L-门冬酰胺酶应联合长春新碱和泼尼松用于急性淋巴细胞白血病或急性未分化白血病的初始诱导。
L-Asparaginase was added to vincristine and prednisone for induction of first remission in 815 children with acute lymphocytic or acute undifferentiated leukemia. This combination resulted in an overall remission rate of 93%. The addition of L-asparaginse to the standard induction regimen using prednisone and vincristine did not significantly increase the morbidity or mortality rate during the induction period. The most common side effect was transient L-asparaginase-induced hyperglycemia. The safe administration of L-asparaginase i.m. and the dose efficacy of 6000 I.U./sq m were confirmed. For these reasons, L-asparaginase should be combined with vincristine and prednisone for the initial induction of children with acute lymphocytic or acute undifferentiated leukemia.